Health Care·Biotechnology·$5.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.53 | N/A | -0.76% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.53 | N/A | -0.76% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook, emphasizing the importance of their clinical programs. They did not provide any updates on future guidance.
Management did not provide specific guidance for future quarters.
The focus remains on ongoing clinical development and strategic partnerships.
This earnings report shows that Scholar Rock continues to operate at a loss, with EPS falling short of expectations. Despite this, the stock rose by 1.48%, likely due to investor optimism about the company's ongoing clinical programs. The lack of revenue data and guidance may leave some investors cautious about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CONSTELLATION ENERGY
Nov 6, 2023